PV Bulletin

Evaluation of Therapeutic Equivalence August 2026

The FDA has published final guidance on the Evaluation of Therapeutic Equivalence for drugs and generic drugs, effective from September 2, 2026.

Primary source: Download the Final Guidance Document

PV Impact Brief

Urgency: HighConfidence: high

What changed

The FDA finalized its guidance on therapeutic equivalence evaluations, replacing the draft guidance issued in July 2022.

Why it matters

This guidance influences how therapeutic equivalence is determined for generic drugs, impacting market competition and drug availability.

Action needed

Focus on therapeutic equivalence evaluations for generics

Relevant for
Regulatory Intelligence Lead
Processes impacted
Country ComplianceSignal Management
Owner

Regulatory Intelligence Lead

Review cadence

Ongoing regulatory updates and feedback collection via industry comment opportunities.

Evidence and confidence

Confidence: highSource updated: Sep 2, 2026

Full briefing

Practical implication

Focus on therapeutic equivalence evaluations for generics

The FDA has announced the final guidance document titled “Evaluation of Therapeutic Equivalence” which clarifies the agency's stance on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes) for multisource prescription drugs. This guidance formalizes recommendations previously outlined in a draft issued in July 2022. It aims to assist state health agencies, prescribers, and pharmacists in educational efforts surrounding drug product selection while also containing healthcare costs.

What changed: The FDA finalized its guidance on therapeutic equivalence evaluations, replacing the draft guidance issued in July 2022.

Why it matters: This guidance influences how therapeutic equivalence is determined for generic drugs, impacting market competition and drug availability.

Practical implication: Focus on therapeutic equivalence evaluations for generics

View original source

  • Source: FDA - News and Events for Human Drugs
  • Published at source: 2026-09-02T00:00:00.000Z
  • Discovered by monitor: 2026-09-02T22:07:12.885Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signals#Guidance#Source-ingestion#Regulator-monitor#Usa#Fda.gov

Related updates for your role

publicFDA · USA · Updated Sep 2, 2026Translated From Korean

Convenience Kit Correction: Medline Issues Correction for Convenience Kits Containing BD ChloraPrep Applicators

Urgency: High

Affected healthcare facilities and distributors must immediately check their stock, remove BD ChloraPrep applicators from all kits, apply over-labels indicating the need for component removal, and notify any customers if they have transferred or resold these products.

Signal ManagementInspection ReadinessRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicFDA · USA · Updated Sep 2, 2026

Early Alert: Convenience Kit Issue from AVID Medical

Urgency: High

Affected users must identify, segregate, and quarantine the kits, add warning labels, and ensure the removal of the recalled components prior to use.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Sep 2, 2026

European Medicines Agency Pre-Authorisation Procedural Guidelines

Urgency: High

Companies must ensure compliance with the Irish language requirements and complete mandatory OMS registration before regulatory submissions to prevent delays.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicFDA · USA · Updated Sep 1, 2026

FDA Adds Boxed Warning to Labeling for Ferric Carboxymaltose Injection (Injectafer) to Describe Risk of Low Phosphate Levels

Urgency: High

Healthcare providers must utilize updated labels and ensure phosphate levels are monitored in at-risk patients and those receiving repeat therapy within three months.

LabelingLabeling Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Labeling Lead, Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward